Avantor (AVTR) vs Pacific Biosciences of California (PACB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pacific Biosciences of California (PACB) has outperformed Avantor (AVTR) over the past year, gaining 94.3% versus a gain of 14.0%. Over five years, AVTR leads with a -60.0% price change compared with -88.8% for PACB. Avantor is the larger company by market cap ($10.38 billion vs $845.5 million), about 12.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTR | PACB |
|---|---|---|
| Share price | $15.35 | $2.72 |
| Market cap | $10.38B | $845.46M |
| 1-day change | -0.52% | +0.74% |
| YTD return | +33.94% | +45.45% |
| 1-year return | +13.96% | +94.29% |
| 5-year return | -59.97% | -88.85% |
| Forward P/E | 17.48 | — |
| EPS (TTM) | $-0.84 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.55B | — |
| Revenue growth (YoY) | -3.41% | — |
| Net income (latest FY) | $-530.20M | — |
| Gross margin | 32.65% | — |
| Operating margin | -3.76% | — |
| Net margin | -8.09% | — |
| 52-week high | $16.38 | $3.44 |
| 52-week low | $7.27 | $1.07 |
| Distance from 52-week high | -6.26% | -20.93% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -3.71% | -20.59% |
| Average volume | 9.45M | 9.85M |
| Shares outstanding | 676.36M | 310.83M |
| Employees | 13,500 | 485 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Avantor is about 12.3 times larger than Pacific Biosciences of California by market value ($10.38B vs $845.46M).
- PACB has outperformed AVTR by 80.3 percentage points over the past year.
About Avantor
AVTR stock →Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.
Industrials · Biotechnology: Laboratory Analytical Instruments · 13,500 employees
About Pacific Biosciences of California
PACB stock →Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 485 employees
AVTR vs PACB FAQ
Which is bigger, Avantor or Pacific Biosciences of California?
Avantor (AVTR) is larger, with a market capitalization of $10.38B compared with $845.46M for Pacific Biosciences of California (PACB).
Which stock has performed better over the past year, AVTR or PACB?
PACB returned +94.29% over the past 12 months, compared with +13.96% for AVTR (price return, excluding dividends). Past performance does not predict future results.
Are Avantor and Pacific Biosciences of California in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.